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fecal microbiome and metabolome 
of infants fed bovine MfGM 
supplemented formula or standard 
formula with breast-fed infants as 
reference: a randomized controlled 
trial
Xuan He1,2, Mariana parenti1, Tove Grip3, Bo Lönnerdal1, Niklas timby3, Magnus Domellöf3, 
olle Hernell3 & carolyn M. Slupsky  1,2
Human milk delivers an array of bioactive components that safeguard infant growth and development 
and maintain healthy gut microbiota. Milk fat globule membrane (MFGM) is a biologically functional 
fraction of milk increasingly linked to beneficial outcomes in infants through protection from 
pathogens, modulation of the immune system and improved neurodevelopment. In the present study, 
we characterized the fecal microbiome and metabolome of infants fed a bovine MfGM supplemented 
experimental formula (EF) and compared to infants fed standard formula (SF) and a breast-fed reference 
group. The impact of MFGM on the fecal microbiome was moderate; however, the fecal metabolome of 
EF-fed infants showed a significant reduction of several metabolites including lactate, succinate, amino 
acids and their derivatives from that of infants fed SF. Introduction of weaning food with either human 
milk or infant formula reduces the distinct characteristics of breast-fed- or formula-fed- like infant fecal 
microbiome and metabolome profiles. Our findings support the hypothesis that higher levels of protein 
in infant formula and the lack of human milk oligosaccharides promote a shift toward amino acid 
fermentation in the gut. MFGM may play a role in shaping gut microbial activity and function.
Breastfeeding influences the development of the gut microbiota according to the degree of exclusivity1,2. This 
is at least partly due to the presence of antimicrobial proteins such as secretory immunoglobulin A, lactoferrin 
and lysozyme in human milk as well as oligosaccharides that function to selectively enhance colonization of spe-
cific groups of gut microbes including Bifidobacterium spp.3–5. Through selection of specific microbes, microbial 
richness and diversity are ultimately reduced2 as they influence the growth of other bacteria6,7, which results in 
modulation of the luminal pH and metabolic profile8,9.
Feeding infant formula has been shown to alter the fecal microbiota from that of breast-fed (BF) infants, 
induce a different serum metabolic profile than in BF infants10–13, and has been associated with increased risk of 
childhood obesity14,15. The difference in serum metabolic profiles may in part be due to differences in the intesti-
nal microbiota, but are also likely due to the substantially higher protein concentration of infant formula as com-
pared to human milk. Specifically, formula-fed (FF) infants have been shown to have higher levels of circulating 
amino acids, amino acid derivatives and urea than BF infants11,12.
There is a substantial quantity of nitrogenous compounds from dietary origin that escape digestion, and these 
compounds are retained in the lumen of the terminal ileum16 to provide substrates for microbial fermentation. 
Amino acids produced by intestinal microbiota are then absorbed and contribute to the host nitrogen pool17. 
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Circulating lysine and threonine, that we previously found to be higher in FF infants13, are considered metabolites 
with a gut microbial origin18–20, as modification of intestinal microbiota via prebiotic supplementation has been 
shown to reduce free amino acids in cecum, colon, serum and liver of adult mice21, and to slightly lower the blood 
urea level of infants22. These studies support the importance of exploring gut microbiota as contributing factors 
to infant metabolism.
The milk fat globule membrane (MFGM) has historically been discarded with the milk fat in the manufac-
turing of bovine milk based infant formula. However, protective activity of MFGM against pathogens and viral 
infections has been shown23,24. Indeed, we found that providing MFGM to young infants in formula reduces the 
incidence of acute otitis media25, and to older infants as a supplement in weaning food reduces the prevalence of 
diarrhea26 and decreases circulating IL-227 as well as trimethylamine-N-oxide27, an oxidized microbial byproduct. 
These studies led to the hypothesis that MFGM may act as a substrate that selectively promotes growth of healthy 
infant gut microbiota, and that supplementing an MFGM concentrate may alter gut microbial composition and 
by-products to a profile that is more similar to an exclusively BF reference group.
To provide a mechanistic explanation regarding the influence of MFGM on gut microbiota, we evaluated the 
fecal microbiome and metabolome of a subgroup of 90 infants who participated in a prospective, double-blind, 
randomized controlled study28,29, where FF infants were randomly assigned to receive a standard infant formula 
(SF) or a bovine MFGM isolate-supplemented, low-energy, low-protein experimental formula (EF) from ~2 until 
6 months of age. An exclusively BF reference group was included in this study. The influence of feeding on the 
composition and metabolic activity of intestinal microbiota was evaluated through secondary analyses of feces 
collected from these infants at baseline (~2 months), 4, 6 and 12 months of age via 16S rRNA amplicon sequenc-
ing and quantitative metabolomic profiling.
Results
characteristics of study population and data exclusion. Out of a total of 240 infants who participated 
in a clinical trial concerning the outcomes of feeding a formula supplemented with a bovine MFGM isolate, which 
initially consisted of BF, n = 80; SF-fed, n = 80, and EF-fed, n = 80 (ClinicalTrials.gov identifier: NCT00624689), 
following exclusions28,29 a subset of 90 infants (15 males and 15 females from each treatment group) were ran-
domly selected for fecal microbiome and metabolome analysis at 2, 4, 6, and 12 months. 96.2%, 96.5% and 82.1% 
of infants in the BF, SF, and EF group respectively were born vaginally. Inclusion criteria for the original study 
were: exclusively formula-fed at <2 months of age or intention to exclusively breastfeed until 6 months of age; 
gestational age at birth: 37–42 weeks; birth weight 2.5–4.5 kg and absence of chronic illness. After data genera-
tion, a few samples were further excluded, including infants who stopped consumption of study formula (n = 2), 
infants who had no record of a food diary (n = 1), infants from the BF group that were heavily mixed-fed (n = 3), 
infants from the FF group who consumed another formula (n = 4), and infants who had a record of antibiotics 
use (n = 3). For fecal metabolome data, samples that contained urea were suspected of being contaminated by 
urine since normal fecal samples do not contain urea due to bacterial urease activity. Therefore, fecal samples 
containing urea were excluded from analysis. The number of samples from each intervention and time point are 
summarized in SI Tables 1, 2.
Study formula intake and complementary food consumption. Our previous work on this cohort 
showed that infants consuming the low-energy, low-protein EF consumed a higher volume, yielding the same 
energy intake as infants consuming SF28. In this randomized subgroup, the intake of formula was only slightly 
higher in the EF group (effect sizes |δ| at each month were negligible or small, SI Fig. 1a). Although EF contains 
less energy than SF (SI Table 3), there was no significant difference in energy intake from consumption of these 
two formulas (Kruskal-Wallis’ H test, effect sizes |δ| at each month were negligible or small, SI Fig. 1c). Starting 
from 4 months, a variety of complementary foods were introduced (SI Fig. 1b) as suggested by the Swedish 
National Food Agency recommendation30. With increasing energy from complementary food, energy from study 
formula decreased between 4 and 6 months of age (SI Fig. 1c). By 6 months, fewer than 30 infants in this sub-
group were still exclusively BF or fed study formula and had no exposure to complementary food (SI Fig. 1b,d). 
To account for the influence of complementary food introduction in our analysis, samples collected at 4 and 6 
months were divided into two subgroups depending on complementary food intake and defined as: with (>10% 
daily energy from) or without (<10% daily energy from) complementary food.
Gut microbiome. To explore the effect of early diet on intestinal microbiota, 16 s rRNA gene sequencing of 
infant feces was performed. Analysis of core microbes of all infants revealed a high prevalence of Bifidobacterium, 
Streptococcus, [Ruminococcus] (from Lachnospiraceae family), Veillonella, Enterococcus and Bacteroides from 2 
to 6 months of age. Over time, as more weaning food was introduced, the relative abundance of Blautia in the 
stool increased (Fig. 1, SI Fig. 2). By 12 months of age, Bifidobacterium, Streptococcus and Bacteroides remained 
highly prevalent. With increases in microbial richness, additional microbes become highly prevalent in the gut 
(Fig. 1).
As expected, higher levels of fecal Streptococcus was observed at 2 months of age (SI Fig. 2), which is likely due 
to bacterial communities arising from the environment, areolar skin and mother’s milk31–33. At 4 and 6 months of 
age when no or low complementary food was introduced, the impact of feeding on the fecal microbial profile was 
the largest (Fig. 2a), with higher abundance of Bifidobacterium species in BF compared with FF infants (Fig. 2c). 
BF infants had a more heterogeneous fecal microbiome profile only during the exclusive feeding period (Fig. 2b). 
By 12 months of age, the fecal microbiome became more homogenous (Fig. 2b) and the BF and FF fecal microbi-
omes became indistinguishable (Fig. 2a).
While fecal Bifidobacteria (Fig. 2c) and other lower abundant microbes (Fig. 2d) were significantly different 
between BF and FF, the difference between the two FF groups was minor. Some infants who consumed EF had a 
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higher percentage of Akkermansia in the stool, and this was more prevalent when no or low complementary food 
was introduced (SI Fig. 3a). At 12 months, the number of individuals with Haemophilus was lower in infants who 
consumed EF compared with those who consumed SF (SI Fig. 3b, ANCOM test followed by FDR correction).
In comparison to BF infants, FF infants showed a slightly higher microbial richness (observed species) at 2 
months (p = 0.077, Kruskal Wallis H test), but not statistically different (or close to statistically different) at other 
time points examined. When applying “Tail” statistics index (a more robust estimate of microbial diversity to 
account for low-abundance rare species34), no significant difference was detected between the two FF groups or 
between BF and FF infants, which may be due to the fact that some of the FF-infants were likely breast-fed after 
delivery for some time before enrolment at ~2 months of age.
fecal metabolome. To evaluate the impact of early diet on intestinal microbial fermentation capability, corre-
sponding fecal metabolites were examined. In agreement with prior studies35, BF infants in this cohort also had higher 
stool frequency and softer/looser stool consistency compared to FF infants25. In this subgroup, we observed signifi-
cantly higher fecal water % and Bristol score in BF infants compared to the FF infants when infants were exclusively 
breast-fed or formula-fed respectively. However, after introduction of complementary food the water content in the 
stool of BF infants decreased to a level similar to both formula groups (Fig. 3a). Comparison of the water content in the 
stool of the formula groups revealed that infants consuming EF had less water in their stool than infants consuming SF 
(Fig. 3a). Since fecal water % was significantly different between groups, instead of normalizing fecal metabolite con-
centration by wet or dry fecal weight, values were expressed in µM.
Fecal metabolite concentrations were associated with the amount of water in the stool. With increased water, 
higher concentrations of sugar monomers (glucose, galactose) and fermentation byproducts from carbohydrate 
metabolism (lactate, 1,2-propanediol, and succinate) were observed. In contrast, the concentration of micro-
bial by-products from amino acid degradation (isobutyrate, isovalerate, dimethylamine, and phenylacetate) were 
associated with lower fecal water % (Fig. 3b–h).
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Figure 1. The core fecal microbiota of infants. The core microbiota is defined as highly prevalent microbes at 
the genus level present in >80% of samples.
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Starting from 2 months of age, a profound difference in the fecal metabolome between BF and FF was 
observed and continued to 4 and 6 months when no or small amounts of complementary food were introduced. 
The effect of diet on the fecal metabolome was reduced in the group with complementary food consumption and 
became indistinguishable at 12 months of age (Fig. 4a, Adonis Test). In agreement with the fecal microbiome data 
(Fig. 2b), BF infants had a more heterogeneous fecal metabolome profile than FF infants, while the difference 
between the two FF groups was almost indistinguishable through Principal Coordinates Analysis (Fig. 4b).
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Figure 2. Analysis of the community structure of fecal microbiota reveals differences between breast-fed (BF, 
green) and formula-fed (Experimental Formula, EF, orange; Standard Formula, SF, red) infants at 2, 4 and 6 
months of age. (a) Principal Coordinates Analysis (PCoA) of the log transformed weighted Unifrac distance. 
The centroids of each cluster (centroid of mass) are calculated as the average of PC1 and PC2 for each group. 
The ellipses were constructed based on multivariate normal distribution at 95% confidence level. The effect size 
(R2) and significance (p-value) between dietary groups were evaluated using permutational MANOVA via the 
Adonis test (permutation = 999). (b) Divergence (the spread within the group) was significantly higher in the 
BF infants during the exclusive feeding period. The measurement of divergence is calculated as 1- the average 
spearman correlation between samples and the overall group-wise average. The group difference was evaluated 
using a Kruskal-Wallis H test follow by the post-hoc Dunn test at p < 0.05. (c,d) Significantly differentiating 
intestinal microbes between the breast-fed (BF, green) and formula-fed (FF, pink) infants. The group differences 
were evaluated using Analysis of Composition of Microbiomes (ANCOM) followed by FDR correction at 
p < 0.05.
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The major difference between the two FF groups was revealed during the exclusive feeding period, with 
lower levels of amino acids (ornithine, isoleucine, glutamate, phenylalanine, tyrosine, valine and glycine), and 
2-hydroxyisovalerate (branched-chain amino acid degradation product), cadaverine (lysine breakdown product), 
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Figure 3. (a) Fecal water % and Bristol score are significantly higher in the breast-fed (BF) infants during the 
exclusive feeding period. The group difference was evaluated using Kruskal-Wallis H test followed by a post-
hoc Dunn test, p < 0.05. Fecal metabolite concentrations are associated with fecal water %. (b) Heatmap of the 
correlation coefficient (Pearson r > 0.4 or <−0.4, p < 0.05) of fecal metabolite concentrations correspond to 
fecal water %. Amount of water in infant stool is positively correlated with fecal concentration of (c) lactate, 
(d) 1,2-propanediol, (e) glucose and (f) galactose and is negatively correlated with (g) isovalerate and (h) 
isobutyrate. The correlation between fecal water % and metabolite concentration were evaluated using data 
collected from 2 months (baseline) and 4 and 6 months (without complementary food).
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and 4-hydroxyphenyllactate (tyrosine breakdown product) in the EF group (Fig. 5, Cliff ’s Delta, Kruskal Wallis 
H test). Lactate and succinate, the two fecal metabolite markers that are positively correlated with amount of 
water in stool (Fig. 3b,c), were also lower in EF group (Fig. 5), and corresponded to the lower fecal water % 
(Fig. 3a). Intermediate metabolites from purine degradation metabolism, including hypoxanthine, were signif-
icantly lower, and inosine tended to be lower in the EF group. Although glycosylation of MFGM protein has 
been reported36, supplementing a bovine MFGM concentrate to the EF did not drive the fecal metabolome to 
the extent expected for human oligosaccharides (HMOs), thus the differences observed were likely derived from 
other active ingredients.
In general, acetate was the most dominant metabolite in the stool (SI Fig. 4). The appearance of larger and 
more diverse fecal sugar monomers are unique markers of breastfeeding, and include N-acetylglucosamine, 
fucose, galactose and glucose. In comparison, the major sugar monomers in the stool of FF infants were mostly 
galactose and glucose, sugar monomers from lactose. By 12 months of age, glucose was the major sugar monomer 
in infant stool. Only a few BF infants at 2 months of age had high levels of detectable HMOs in the stool, and the 
majority of these infants had lower concentrations of by-products from complex carbohydrate degradation (SI 
Fig. 4).
As breastfeeding continued, although more complementary food was introduced, the signature of breast-
feeding persisted in the stool. BF infants exhibited higher levels of 4-hydroxyphenyllactate, fucose, lactate, 
1,2-propanediol, pyruvate, and myo-inositol than the FF infants (Fig. 6a). In contrast, the FF-specific met-
abolic signature, included higher levels of butyrate, propionate, isobutyrate, isovalerate, phenylacetate and 
4-hydroxyphenylacetate, which were no longer significant when more “carbohydrate-rich” complementary foods 
were introduced (Fig. 6b, Kruskal-Wallis H test). The complete list of differential metabolites between BF and FF 
stool is present in SI Fig. 5.
Discussion
Intestinal microbiota adapts and responds to the availability and distribution of fermentable substrates deliv-
ered from food. After escape from digestion, lactose and complex carbohydrates (including free HMOs, 
protein-derived and host-derived glycans) become substrates for gut microbial fermentation. Introduction of 
complementary food to either BF or FF infants disrupts the BF- or FF- specific fecal profile (Figs 2a, 4a). As 
weaning begins, the infant gut microbiota is exposed for the first time to a new range of nutrients, and as a result, 
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Figure 4. The fecal metabolome reveals differences between breast-fed (BF, green) and formula-fed 
(Experimental Formula, EF, orange; Standard Formula, SF, red) infants at 2, and 4 & 6 months of age. (a) 
Principal Coordinates Analysis (PCoA) of the Euclidean distance matrix of the generalized log transformed 
fecal metabolite concentration data. The centroids of each cluster (centroid of mass) were calculated as the 
average PC1 and PC2 of all samples for each group. The ellipses were constructed based on multivariate normal 
distribution at 95% confidence level. The effect size (R2) and significance (p-value) between dietary groups were 
evaluated using permutational MANOVA via the Adonis test (permutation = 999). (b) Divergence (the spread 
within each group) is significantly higher in BF infants during the exclusive feeding period. The measurement of 
divergence was calculated as 1- the average spearman correlation between samples and the overall group-wise 
average. The group difference was evaluated using Kruskal-Wallis H test follow by post-hoc Dunn test, p < 0.05.
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inter-individual variation becomes less pronounced and the composition starts to resemble that of an adult-like 
microbiota. The abundance of Bifidobacterium, the predominant genus of the gut microbiota of BF infants, was no 
longer significantly higher than in FF infants following introduction of complementary food (Fig. 2c). However, 
before 6 months of age, if breastfeeding continued, complementary food introduction had a negligible effect on 
the key BF-specific fecal metabolite markers (Fig. 6a).
In this study, a bovine MFGM concentrate was supplemented to infant formula as an attempt to narrow 
the metabolic and microbial gap between BF and FF infants. Although some of the MFGM proteins are gly-
cosylated36, which could provide a substrate for microbial fermentation, the amount of bovine MFGM supple-
mented in the current study is lower (approximately 0.48 g/L) compared to a recent study on rat pups (1.2 g/L) 
that showed a significant change in colon microbial composition and diversity with MFGM supplementation37. 
In comparison to the difference in the serum metabolome and other biochemical, clinical and cognitive measure-
ments, the influence of MFGM supplementation on the overall oral microbiota38 and fecal microbiota (Figs 2a, 
4a) was moderate and did not override the effect of formula, as infants who consumed MFGM-supplemented 
formula were more similar to those who consumed SF than those who were breast-fed. However, during the 
exclusive feeding period, lower concentrations of a few metabolites were observed in the EF in compared to the 
SF group (Fig. 5), providing a complementary view toward a potential functional change in the gut microbial 
community. Fecal hypoxanthine was lower in the EF-fed infants (Fig. 5), which is in line with the presence of 
hypoxanthine dehydrogenase/oxidase in bovine MFGM39. The reduced level of fecal hypoxanthine, together with 
the high abundance of Akkemansia in a few of the EF-fed infants (SI Fig. 3a), should be further confirmed in a 
larger clinical study. At 12 months of age, the incidence of having a high prevalence of fecal Haemophilus, a genus 
consisting of several pathogens, was lower in EF-fed infants (SI Fig. 3b). This observation suggests a potential 
long term impact of MFGM supplementation on the fecal microbiota that has not been reported elsewhere, and 
builds on previous studies in this cohort showing a lower incidence of acute otitis media in EF-fed infants at 6 
months of age25. Further studies with larger sample sizes and targeted pathogen detection are needed to confirm 
these observations.
In comparison to formula-feeding, human milk consumption yielded higher levels of lactate, pyruvate, 
1,2-propanediol, myo-inositol, fucose and 4-hydroxyphenyllactate in the stool (Fig. 6a). The large amounts of lac-
tate in BF infant stool reported here and elsewhere40, are expected to be produced by Bifidobacterium, Bacteroides, 
Enterococcus and Streptococcus41,42 that are also primary colonizers of the infant gut (Fig. 1). However, in com-
parison to other bacterial genera, the metabolic capability of the species belonging to the Bifidobacteria genus is 
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Figure 5. Fecal metabolites that are significantly different between formula-fed infants who consumed standard 
formula (SF, red) and experimental formula (EF, orange).
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highly conserved with enriched saccharolytic modules in their genomes that are specialized for efficient HMO 
utilization43. Several Bifidobacteria subspecies (including B. longum subsp. infantis44, B. longum subsp. suis 
BSM11-545, B. kashiwanohense45, and B. bifidium46) harbor α-fucosidases and demonstrate the ability to produce 
1,2-propanediol from fucose and fucosyllactose45. Bifidobacterium has been shown to produce a considerable 
amount of 4-hydroxyphenyllactate in vitro47, providing an explanation for the high 4-hydroxyphenyllactate found 
in the stool of BF infants.
While breastfeeding-derived fecal metabolic markers are associated with the utilization of carbohydrates, 
FF induces higher levels of branched chain fatty acids (BCFAs, isobutyrate and isovalerate) and phenylacetate 
(Fig. 6b), which are microbial end-products of peptide and amino acid fermentation. These have been shown to 
be elevated in in vitro incubation of intestinal content48,49, colon content from rodents, and in stool from individu-
als consuming high protein diets50–52. The higher fecal levels of propionate and butyrate in FF infants (Fig. 6b and 
elsewhere53,54) may be due to degradation of certain amino acids55 or production by species from the Eubacterium 
genus (Fig. 2d), which demonstrate an ability to utilize lactate and produce butyrate and propionate56,57.
In accordance with the higher protein intake provided by formula, stool ammonia has been reported to be 
significantly higher in exclusively FF infants compared to their BF counterparts58 which can be explained by 
excess dietary protein that escapes digestion59. This further implies that the intestinal microbiota in FF infants is 
likely to participate in significant catabolism of amino acids in the intestinal lumen. To an extent, the presence of 
ammonia reduces the uptake and utilization of short chain fatty acids (SCFAs) by colonocytes, and subsequently 
decreases the production of ketone bodies and CO2 50,60–62; therefore, the elevated butyrate level in the stool of FF 
infants (Fig. 6b) could also, in part, be due to reduced uptake by the colonocytes. Furthermore, ammonia can be 
easily absorbed by colonocytes, enter the circulation, and be detoxified to urea in the liver. This may contribute to 
the high urea concentration observed in the serum metabolome of FF infants13.
Infant formula contains considerably more protein than human milk63. A high protein content in the diet 
not only provides substrates for amino acid degradation, but may also induce protease activity in the colon50. In 
addition, proteases are more active in the neutral to alkaline pH range64. From the proximal to the distal colon, 
intestinal luminal pH65 and protease activity66,67 progressively increases as the amount of SCFA declines65,68. Gut 
microbial carbohydrate fermentation is also higher in the proximal colon69, whereas protein fermentation mostly 
takes place in the distal colon67. We speculate that carbohydrate fermentation in the proximal colon influences 
protein fermentation in the distal colon. When a substantial amount of HMOs reach the colon, rapid microbial 
fermentation is induced. As high total acids are produced from complex carbohydrate fermentation, intestinal 
bicarbonate buffering capacity is insufficient, and thus induces significant acidification of the lumen70,71. It has 
been shown that BF infants with greater utilization of HMOs exhibit a lower stool pH72, and rats consuming 
inulin alone or with Bifidobacterium longum have significantly reduced caecal pH and ammonia concentration73. 
4-
HP
LA
Fu
co
se
La
ct
at
e
1,
2-
Pr
op
an
ed
io
l
Py
ru
va
te
m
yo
-In
os
ito
l
0.0
2.5
5.0
7.5
10.0
12.5
4-
HP
LA
Fu
co
se
La
ct
at
e
1,
2-
Pr
op
an
ed
io
l
Py
ru
va
te
m
yo
-In
os
ito
l
4-
HP
LA
Fu
co
se
La
ct
at
e
1,
2-
Pr
op
an
ed
io
l
Py
ru
va
te
m
yo
-In
os
ito
l
4-
HP
LA
Fu
co
se
La
ct
at
e
1,
2-
Pr
op
an
ed
io
l
Py
ru
va
te
m
yo
-In
os
ito
l
ge
ne
ra
l l
og
 tr
an
sf
or
m
ed
 fe
ca
l c
on
ce
nt
ra
tio
n
ge
ne
ra
l l
og
 tr
an
sf
or
m
ed
 fe
ca
l c
on
ce
nt
ra
tio
n
2 Months (Baseline) 4 & 6 Months (without Complementary Food) 4 & 6 Months (with Complementary Food) 12 Months
* ** * * * * * * * * **** **
0
3
6
9
12
4-
HP
A
Bu
ty
ra
te
Is
ob
ut
yr
at
e
Is
ov
al
er
at
e
Ph
en
yla
ce
ta
te
Pr
op
io
na
te
4-
HP
A
Bu
ty
ra
te
Is
ob
ut
yr
at
e
Is
ov
al
er
at
e
Ph
en
yla
ce
ta
te
Pr
op
io
na
te
4-
HP
A
Bu
ty
ra
te
Is
ob
ut
yr
at
e
Is
ov
al
er
at
e
Ph
en
yla
ce
ta
te
Pr
op
io
na
te
4-
HP
A
Bu
ty
ra
te
Is
ob
ut
yr
at
e
Is
ov
al
er
at
e
Ph
en
yla
ce
ta
te
Pr
op
io
na
te
* * **** ** *** * *
2 Months (Baseline) 4 & 6 Months (without Complementary Food) 4 & 6 Months (with Complementary Food) 12 Months
a
b
*
BF FF
Figure 6. Significantly differentiating fecal metabolites that are (a) higher and (b) lower in breast-fed (BF, 
green) than formula-fed (FF, red) infants. The group differences were evaluated using Kruskal-Wallis H test 
by FDR correction at p < 0.05. The complete list of differentiating metabolites is in SI Fig. 5. Abbreviation: 
4-HPLA: 4-hydroxyphenyllactate, 4-HPA: 4-hydroxyphenylacetate.
9Scientific RepoRtS |         (2019) 9:11589  | https://doi.org/10.1038/s41598-019-47953-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
This further supports the observation that acidic pH can decrease microbial uptake of most amino acids, reduce 
the rate of amino acid fermentation and subsequently decrease the net production of ammonia and BCFA48.
Since the amount of oligosaccharides is low in infant formula, the lack of complex carbohydrate substrates 
from the diet results in a higher stool pH in FF infants compared to BF infants40,54. In contrast, incorporating 
galacto-oligosaccharides and fructo-oligosaccharides in infant formula reduces the stool pH to a level more sim-
ilar to BF infants53,54,74–76. Interestingly, none of the key metabolites that are different between BF and FF infants 
(Fig. 6) were observed in our previous work when comparing BF and FF rhesus monkeys77. Rhesus monkey milk 
contains lower oligosaccharide concentrations than human milk78,79. Therefore, the difference in fecal metabo-
lome of BF and FF human infants observed here could be largely explained by the availability of complex carbo-
hydrates in the diet for microbial utilization.
During the exclusive feeding period, FF infants had less water content in the stool (Fig. 3a). In addition, 
a harder stool and a longer intestinal transit time have been associated with carbohydrate deprivation and a 
more extensive proteinaceous substrate breakdown80,81. Dietary inclusion of fermentable complex carbohy-
drates has been shown to be a promising approach to reduce the rate of microbial protein fermentation82–84. 
Indeed, infants who consumed formula containing non-digestible oligosaccharides (fructo-oligosaccharides, 
galacto-oligosaccharides) had faster transit times and softer and more frequent stools22,74–76,85–87. Here, we 
observed that a watery stool is associated with an excess amount of sugar monomers and by-products from 
oligosaccharide fermentation (Fig. 3b–f). These microbial-derived products, if not utilized by the host or other 
microbes, may also act as organic osmolytes, drawing water from the epithelium into the lumen, leading to an 
even softer stool.
One strength of the present study is the double-blind randomized design among FF infants. Comparisons 
between FF and BF infants in the present study should be made with caution since these two groups were not 
randomized and potential confounding factors involving feeding choice cannot be ruled out. Another limitation 
of this study is the lack of information on the volume of human milk consumed and mother’s milk composition. 
It is well established that the composition of HMOs is driven by maternal secretor status and Lewis Blood group 
status88,89. Furthermore, by 12 months of age, only 6 infants in the BF group had a record of breast milk consump-
tion. Although Bäckhed et al. have shown that the influence of breastfeeding on the gut microbiome remains at 12 
months if breastfeeding persists1, we were not able to confirm this in the present study. Additionally, a large num-
ber of infants in all dietary groups consumed probiotics (containing Lactobacillus) during the study intervention 
period. Although the relative abundance of Lactobacillus in stool was low (<3%), we cannot rule out its potential 
contribution to the infant fecal metabolome90.
conclusions
The results obtained in the present study clearly show the importance of early life nutrition on the community 
profile and functional characterization of intestinal microbiota. Breastmilk or formula-feeding as well as com-
plementary food influence gut microbiota and the luminal environment. Building on previous work13,25,28,29,38,91 
on this cohort, this study provides information on the effect of feeding on gut microbiota in the first year of 
life. The different fecal microbiomes are reflected by differences in fecal water % and concentration of microbial 
by-products in the stool. With limited oligosaccharides present and high protein levels in infant formula, we 
speculate that the difference observed between the BF and FF infant fecal microbiome and metabolome can be 
explained by an alteration in the availability and microbial utilization of carbohydrates and proteins as energy 
substrates. The difference between the fecal microbial taxonomic profiles of MFGM supplemented EF and SF was 
moderate in comparison to the distinct difference between BF and FF infants. However, an influence of MFGM 
on the fecal metabolome was observed, and may be associated with a change in microbial activity and function. 
Further studies are needed to explore the linkage between the potential antimicrobial property of MFGM proteins 
and the specific alteration we observed in the fecal metabolome.
Methods
Study population. This double-blinded, parallel randomized controlled trial took place at Umeå University 
Hospital, Umeå, Sweden after approval by the Regional Ethical Review Board in Umeå (Dnr 07-083 M) for all 
experimental protocols, and obtaining both oral and written informed consent from the parents/caregivers before 
inclusion. The study was registered at clinicaltrials.gov (NCT00624689, February 27, 2008), and was conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Study formula. SF infants consumed BabySemp1 (Semper AB, Sundbyberg, Sweden) and EF infants con-
sumed a formula modified from BabySemp1 with the addition of bovine MFGM-enriched whey protein concen-
trate (Lacprodan® MFGM-10; Arla Foods Ingredients, Viby J, Denmark) to account for 4% of the total protein 
in the EF. The macronutrient composition of the EF and SF has been described previously and also available in 
SI Table 3.
Estimation of nutrient intake. 3-day food diary was recorded by parents every month over 3 consecutive 
days at 2, 3, 4, 5, 6 and 12 months of age. All food and drink that a child consumed were recorded either by weight 
(grams) or volume (milliliters, deciliters, tablespoons or teaspoons) by the parents using household measures and 
kitchen utensils. Taste portions were noted as if the intake volume was <15 mL. Brand name and manufacturer 
name were recorded if the food/drink consumed was a commercial product. The nutrient intake of each comple-
mentary food was calculated according to the Swedish National Food Agency Database and food labels. Use of 
medications, vitamins or dietary supplementations was documented. Persistence of breastfeeding was reported 
but the volume was not.
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Stool collection procedure. Before or at the time of each visit, stool samples were collected by parents into 
a plastic container. The samples were immediately frozen at −80 °C or, if the sample was collected at home, frozen 
at −20 °C in a home freezer before transportation to the clinic and storage at −80 °C. The maximum storage time 
at −20 °C was 3 days.
fecal metabolite extraction. After manual homogenization with a sterile microspatula, avoiding undi-
gested food, approximately 250 mg of fecal material were weighted and then extracted by vigorously vortexing in 
1.5 ml ice-cold Dulbecco’s phosphate buffered saline (DPBS, 1X, pH 7.4) followed by centrifugation. The pellet 
was collected, frozen at −80 °C, and subsequently lyophilized to determine fecal dry weight (Labconco FreeZone 
4.5 L Freeze Dry System, Labconco, Kansas city, MO). The supernatants were carefully collected and sequentially 
filtered through a syringe filter with 0.22 µm pore size (Millex-GP syringe filter, Millipore, Billerica, MA) and an 
ultracentrifugal filter with a 3k Da molecular weight cut-off (Amicon ultra centrifugal filter, Millipore, Billerica, 
MA) to remove microbes and excess proteins. 23 µl of internal standard (DSS-d6 in 5 mM, with 0.2% sodium 
azide in 99.8% D2O) was added to 207 µL filtrate. The pH of each sample was adjusted to 6.8 ± 0.1 by adding small 
amounts of NaOH and HCl to minimize pH-based peak movement. 180 µL aliquots were subsequently trans-
ferred to 3 mm Bruker NMR tubes (Bruker, Brillerica, MA) and stored at 4 °C until spectral acquisition.
NMR acquisition, data processing and quantification. 1H NMR spectra were acquired at 298K using 
the NOESY 1H presaturation experiment (‘noesypr1d’) on Bruker Avance 600 MHz NMR spectrometer (Bruker 
BioSpin, Germany). Spectral acquisition and processing parameters are identical to our previous work from 
this cohort13. Spectra were manually processed and profiled using Chenomx NMR Suite v8.3 (Chenomx Inc, 
Edmonton, Alberta, Canada). The concentration of fecal metabolites were estimated as:
× ×
+utput from Chenomx fecal water estimate
fecal water estimate
O 230
207
1500,
where fecal water estimate is wet weight (mg) − dry weight (mg).
Stool water % and bristol score. Stool water % was calculated as (wet − dry)/wet stool weight * 100. 
Bristol stool score92, a scale from category 1 to 7 that indicates from hard to watery stool, was documented by one 
laboratory technician to ensure consistency.
fecal microbial DnA extraction and library preparation. To minimize the freeze-thaw cycle, the 
fecal metabolite and microbial DNA were extracted on the same day for each sample. Approximately 250 mg 
of fecal material was extracted according to the HMP protocol using MoBio PowerLyzer PowerSoil DNA iso-
lation kit (MoBio, Carlsbad, CA)93. The HMP protocol was modified from the manufacturer’s instruction as 
follows: (1) samples were heated at 65 °C for 10 min and then 95 °C for 10 min after adding C1 solution; (2) 
bead-beating of the samples was performed at 6.5 m/s for 1 min followed by 5 min rest, and bead-beating again 
for 1 min (FastPrep-24 bead beater, MP Bio, Solon OH); and (3) after bead beating, samples were centrifuged for 
3 min to ensure pellets fully formed. The DNA purity was determined spectrophotometrically (NanoDrop 2000C 
Spectrophotometer, Thermo Fisher Scientific, Waltham, MA, USA).
The V4 region of the 16S rRNA gene was targeted using F515/R806 primers94 modified according to Bokulich 
et al.95 to contain an illumina adapter sequence on the forward primer. An 8 bp Hamming error-correcting bar-
code was attached to the 3′ end of the forward primer to enable sample multiplexing. PCR reactions were per-
formed in 20 µL reaction volumes following the protocol developed by Gohl et al.96. PCR reactions contained 
DNA template, DMSO (Fisher Scientific, Waltham, MA), 5X KAPA HiFi Buffer (KAPA Biosystems, Woburn, 
MA), dNTP Mix (10 mM), KAPA HiFi HotStart Polymerase (KAPA Biosystems, Woburn, MA), PCR-grade water 
(MoBio, Carlsbad, CA), DNA template and primers. The ideal volume of DNA template in the PCR reaction was 
estimated using a dilution series experiment followed by a quality check via gel electrophoresis of the amplicon 
product. The PCR reaction consisted of an initial 95 °C for 5 min followed by a 25-cycle program of 20 s at 98 °C 
for denaturation, 15 s at 55 °C for annealing, 60 s at 72 °C for primer extension and a final extension of 72 °C for 
10 min. All reactions were amplified in duplicate and combined prior to purification.
All amplified PCR products were quality checked by gel electrophoresis. The band intensity (around 380 bp) 
was visualized using SYBR safe DNA stain (Invitrogen) and its quantity (in ng/µL) was estimated using a molec-
ular ladder with known concentration (BioRad EZ ladder 1 kb) through ImageLab software (v5.2.1, BioRad, 
Hercules, CA). Amplicons were pooled at equimolar ratio and purified using the QIAquick PCR Purification Kit 
(QIAGEN, Hilden, Germany) using a modified protocol from the manufacturer’s instruction. To maximize DNA 
yield and purity in the final library, amplicons were first combined into 12 separate libraries (not exceeding the 
column DNA capacity) and each were cleaned according to the manufacturer’s instruction. The final elusion was 
made by eluting the first column with 60 µL of elusion buffer and all subsequent column were eluted from the 
filtrate from the previous column. A Purified amplicon library was quality checked by Bioanalyzer and submitted 
to the UC Davis Genome Center DNA Technologies Core for 250 bp paired-end sequencing on the Illumina 
MiSeq platform.
To avoid airborne contamination during extraction as described in Salter et al.97, the DNA extraction was 
performed using PCR clean and sterile filter pipette tips and in a cleaned biosafety cabinet sanitized by UV for at 
least 30 min prior to the experiment followed by surface decontamination by DNAaway (Thermo Scientific). One 
negative control “blank sample” from extraction of PCR-grade water (MoBio, Carlsbad, CA) was included for 
each batch. This batch sample was subsequently amplified via PCR, visually inspected using gel electrophoresis 
and included in the final DNA library.
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Analysis of 16 s amplicon sequence. A sliding window trimming of 4 bases wide on the low quality bases 
(quality score <20) was performed using Trimmomatic98 (version 0.33) at the end of both forward and reverse 
sequences. About 0.5% poor quality sequences were excluded. The subsequent sequence data was analyzed using 
the Quantitative Insights Into Microbial Ecology (QIIME) platform99 (version 1.9.0). Forward and reverse reads 
were joined using Fastq-join100 via join_paired_end.py where at least 50 bp of overlapping was required and the 
maximum difference was below 5%. About 74.16% of the sequences remained after joining paired end reads. 
The subsequent joined sequences were preprocessed and demultiplexed according to the following criteria: (1) 
removal of primer sequences; (2) minimum acceptable Phred quality score Q > 20: and (3) no barcode mis-
match allowed. Closed OTU picking at 97% identity was done using sortmerna101 against the greengenes database 
(greengenes 13_8)102. After removing singletons (0.011% of total sequences), the OTU table was normalized by 
the copy number using normalize_by_copy_number.py function developed in PICRUSt (version 1.1.3)103.
Statistical analysis. Statistical computing and graphical generation were performed using the R program-
ing environment. OTU table handling was achieved using phyloseq and the microbiome package. α-diversity and 
β-diversity distance matrices were computed using DiversitySeq and the vegan package, respectively. Generalized 
log transformation (defined as log(y + sqrt(y2 + lambda))) was applied to all metabolomics data where lambda is 
1. Principal coordinate analysis was computed using the pcoa function from the ape package. Adonis, a nonpar-
ametric implementation of a permutational analysis of variance, was computed using the adonis function from 
vegan with permutation set at 999. The spread (homogeneity) within a group was determined as 1 - cor where cor 
is the average spearman correlation between samples and the overall group-wise average. This feature is imple-
mented in the divergence function in the microbiome package.
The differential analysis for the microbiome was computed at the genus level using ANCOM104 and controls 
for False Discovery Rate (FDR). A pseudo count value of 0.001 was added for the relative abundance data. For 
other data, significance between groups was evaluated using the Kruskal-Wallis test (kruskal.test function) and 
p-values from the Kruskall-Wallis test were further adjusted by FDR (p.adjust(, method = ‘fdr’)). The overall level 
of significance was set at p < 0.05.
Effect size between BF and FF and between SF and EF was evaluated using Cliff ’s delta (δ) statistics using the 
cliff.delta function from effsize package. The 95% confidence interval of each computed Cliff ’s delta was estimated 
assuming a normal distribution (use.normal = TRUE). The magnitude was assessed using the thresholds sug-
gested by Romano et al.105, where |δ| < 0.147 corresponds to negligible, |δ| < 0.33 corresponds to small, |δ| < 0.474 
corresponds to medium, otherwise large.
The square of Pearson’s correction coefficient (r2) was computed using cor, (method = “pearson”) to evaluate 
the strength of the correlation. All plots were generated using ggplot2.
Data Availability
16S sequencing data from this study was deposited in the European Nucleotide Archive (accession code 
ERP112481) and Qiita106 (study ID: 12021). NMR spectra and relevant metadata are available from the corre-
sponding author on request.
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